Carol E. Cass

18.1k total citations · 2 hit papers
267 papers, 14.4k citations indexed

About

Carol E. Cass is a scholar working on Physiology, Molecular Biology and Oncology. According to data from OpenAlex, Carol E. Cass has authored 267 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Physiology, 109 papers in Molecular Biology and 79 papers in Oncology. Recurrent topics in Carol E. Cass's work include Adenosine and Purinergic Signaling (165 papers), Drug Transport and Resistance Mechanisms (48 papers) and HIV/AIDS drug development and treatment (42 papers). Carol E. Cass is often cited by papers focused on Adenosine and Purinergic Signaling (165 papers), Drug Transport and Resistance Mechanisms (48 papers) and HIV/AIDS drug development and treatment (42 papers). Carol E. Cass collaborates with scholars based in Canada, United Kingdom and United States. Carol E. Cass's co-authors include James D. Young, Stephen A. Baldwin, Sylvia Y.M. Yao, John R. Mackey, Alan R. P. Paterson, Amy M.L. Ng, Vijaya L. Damaraju, Mabel W.L. Ritzel, Delores Mowles and Anne E. King and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Carol E. Cass

266 papers receiving 14.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The equilibrative nucleoside transporter family, SLC29

2004 548 citations Sylvia Y.M. Yao, Stephen A. Baldwin et al. profile →
Gastric Adenocarcinoma

2005 547 citations Carol E. Cass, John R. Mackey et al. profile →

Peers

Countries citing papers authored by Carol E. Cass

Since Specialization

Citations

This map shows the geographic impact of Carol E. Cass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol E. Cass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol E. Cass more than expected).

Fields of papers citing papers by Carol E. Cass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol E. Cass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol E. Cass. The network helps show where Carol E. Cass may publish in the future.

Co-authorship network of co-authors of Carol E. Cass

This figure shows the co-authorship network connecting the top 25 collaborators of Carol E. Cass. A scholar is included among the top collaborators of Carol E. Cass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol E. Cass. Carol E. Cass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Breast cancer associated germline structural variants harboring small noncoding RNAs impact post-transcriptional gene regulation 2018 ·Scientific Reports ·(unknown), Preethi Krishnan, Carol E. Cass, Roland Hubaux, Wan L. Lam, Yutaka Yasui, Sambasivarao Damaraju	11
2	Synthesis and preclinical characterization of 1-(6′-deoxy-6′-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6′-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia 2016 ·Bioorganic & Medicinal Chemistry ·Thomas Wanek, (unknown), (unknown), (unknown), Christoph Denk, Johann Stanek, Severin Mairinger, Thomas Filip, Michael Sauberer, (unknown), Alexander Traxl, (unknown), K. Mereiter, Friedrich Hammerschmidt, Carol E. Cass, Vijaya L. Damaraju, Oliver Langer, Claudia Kuntner	12
3	A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer 2015 ·Clinical Breast Cancer ·Michael B. Sawyer, Edith Pituskin, Sambasivarao Damaraju, Robert R. Bies, Larissa J. Vos, Carla M. Prado, Michelle Kuzma, Andrew Scarfe, Mark Clemons, Katia Tonkin, Heather‐Jane Au, Sheryl Koski, Anil A. Joy, Michael Smylie, Karen King, (unknown), Vijaya L. Damaraju, John Hanson, Carol E. Cass, John R. Mackey	17
4	Cellular Influx, Efflux, and Anabolism of 3-Carboranyl Thymidine Analogs: Potential Boron Delivery Agents for Neutron Capture Therapy 2013 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Vijaya L. Damaraju, Delores Mowles, Michael B. Sawyer, Rohit Tiwari, Hitesh K. Agarwal, Ahmed Khalil, Sherifa Hasabelnaby, A. Goudah, Robin J. Nakkula, Rolf F. Barth, Carol E. Cass, Staffan Eriksson, Werner Tjarks	11
5	Transport of A1 Adenosine Receptor Agonist Tecadenoson by Human and Mouse Nucleoside Transporters: Evidence for Blood-Brain Barrier Transport by Murine Equilibrative Nucleoside Transporter 1 mENT1 2013 ·Drug Metabolism and Disposition ·Eve‐Irene Lepist, Vijaya L. Damaraju, Jing Zhang, Wendy P. Gati, Sylvia Y.M. Yao, Kyla M. Smith, Edward Karpinski, James D. Young, Kwan Leung, Carol E. Cass	9
6	Nucleobase Transport by Human Equilibrative Nucleoside Transporter 1 (hENT1) 2011 ·Journal of Biological Chemistry ·Sylvia Y.M. Yao, Amy M.L. Ng, Carol E. Cass, Stephen A. Baldwin, James D. Young	100
7	Conserved Glutamate Residues Glu-343 and Glu-519 Provide Mechanistic Insights into Cation/Nucleoside Cotransport by Human Concentrative Nucleoside Transporter hCNT3 2009 ·Journal of Biological Chemistry ·Melissa D. Slugoski, Kyla M. Smith, Amy M.L. Ng, Sylvia Y.M. Yao, Edward Karpinski, Carol E. Cass, Stephen A. Baldwin, James D. Young	14
8	Evidence for copurification of micronuclei in sucrose density gradient-enriched plasma membranes from cell lines 2009 ·Analytical Biochemistry ·Sambasivarao Damaraju, Nancy R. Zhang, Nan Li, (unknown), Vijaya L. Damaraju, Jennifer Dufour, C.L. Santos, Xuejun Sun, John R. Mackey, David S. Wishart, Carol E. Cass, Liang Li	2
9	Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells 2008 ·Cancer Research ·Jie Cai, Vijaya L. Damaraju, Normand Groulx, Delores Mowles, (unknown), Morris J. Robins, Carol E. Cass, Piet Gros	78
10	Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer 2008 ·Gastroenterology ·James J. Farrell, Hany Elsaleh, M. López García, Raymond Lai, Ali Ammar, William F. Regine, Ross A. Abrams, Al B. Benson, John S. Macdonald, Carol E. Cass, Adam P. Dicker, John R. Mackey	331
11	A Proton-mediated Conformational Shift Identifies a Mobile Pore-lining Cysteine Residue (Cys-561) in Human Concentrative Nucleoside Transporter 3 2008 ·Journal of Biological Chemistry ·Melissa D. Slugoski, Amy M.L. Ng, Sylvia Y.M. Yao, Kyla M. Smith, (unknown), Jing Zhang, Edward Karpinski, Carol E. Cass, Stephen A. Baldwin, James D. Young	16
12	Chapter 6 Renal Conservation of Folates 2008 ·Vitamins and hormones ·Vijaya L. Damaraju, Carol E. Cass, Michael B. Sawyer	7
13	Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene 2005 ·Pharmacogenetics and Genomics ·Sambasivarao Damaraju, Jing Zhang, Frank Visser, (unknown), Jennifer Dufour, Kyla M. Smith, Melissa D. Slugoski, Mabel W.L. Ritzel, Stephen A. Baldwin, James D. Young, Carol E. Cass	28
14	Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy 2003 ·Oncogene ·Vijaya L. Damaraju, Sambasivarao Damaraju, James D. Young, Stephen A. Baldwin, John R. Mackey, Michael B. Sawyer, Carol E. Cass	261
15	Correspondence Re: J. R. Mackey et al., ImmunohistochemicalVariation of Human Equilibrative Nucleoside Transporter 1 Protein inPrimary Breast Cancers. Clin. Cancer Res., 8: 110ndash;116, 2002. 2003 ·Clinical Cancer Research ·Laith Dabbagh, Robert Coupland, Carol E. Cass, John R. Mackey	13
16	Mutation of Residue 33 of Human Equilibrative Nucleoside Transporters 1 and 2 Alters Sensitivity to Inhibition of Transport by Dilazep and Dipyridamole 2002 ·Journal of Biological Chemistry ·Frank Visser, Mark F. Vickers, Amy M.L. Ng, Stephen A. Baldwin, James D. Young, Carol E. Cass	110
17	Acquisition of Human Concentrative Nucleoside Transporter 2 (hCNT2) Activity by Gene Transfer Confers Sensitivity to Fluoropyrimidine Nucleosides in Drug-Resistant Leukemia Cells 2001 ·Molecular Pharmacology ·(unknown), M Selner, James D. Young, Carol E. Cass	48
18	Molecular Identification and Characterization of Novel Human and Mouse Concentrative Na+-Nucleoside Cotransporter Proteins (hCNT3 and mCNT3) Broadly Selective for Purine and Pyrimidine Nucleosides (System cib) 2001 ·Journal of Biological Chemistry ·Mabel W.L. Ritzel, Amy M.L. Ng, Sylvia Y.M. Yao, Kathryn Graham, Shaun Loewen, Kyla M. Smith, R. Gary Ritzel, Delores Mowles, Pat Carpenter, Xing‐Zhen Chen, Edward Karpinski, Ralph J. Hyde, Stephen A. Baldwin, Carol E. Cass, James D. Young	283
19	Interactions of a High Mobility Group-like Protein with Human Mitochondrial DNA 1997 ·Archives of Biochemistry and Biophysics ·Huayan Wang, Bernard D. Lemire, Carol E. Cass, Joël H. Weiner, Marek Michalak, Dyal Singh, Larry Fliegel	1
20	Transport of uridine and 3-deazauridine in cultured human lymphoblastoid cells. 1984 ·PubMed ·(unknown), Alan R. P. Paterson, (unknown), Carol E. Cass	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact